Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. (Q53241704)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

ChEBI release 2020-05-28

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

José Guzmán-Esquivel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

José Guzmán-Esquivel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Luz Margarita Baltazar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Francisco Espinoza-Gomez

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Augusto Rojas-Martinez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rocio Ortiz-Lopez

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rafael González-Alvarez

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Alejandro D Soriano-Hernández

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Hector R Galvan-Salazar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Alejandrina Rodriguez-Hernandez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rafael Martinez-Martinez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Laura L Valdez-Velazquez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Daniel A Montes-Galindo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

10 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

International Urology and Nephrology

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

471-477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660425%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Emerging therapies in castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Current prostate cancer treatments: effect on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

NSAIDs and chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

COX-2 inhibitors in cancer treatment and prevention, a recent development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Molecular targets of nitric-oxide-donating aspirin in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Comparative toxicity of non-steroidal anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Organotin meclofenamic complexes: Synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid - novel anti-tuberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Role for prostaglandins in the regulation of type 1 11beta-hydroxysteroid dehydrogenase in human granulosa-lutein cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-0012-0

A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment

21 January 2018

1 reference

12 December 2020

Basic fibroblast growth factor in human prostate cancer cells

1 reference

12 December 2020

[EAU guidelines on prostate cancer].

1 reference

12 December 2020

Inflammation and prostate cancer

1 reference

12 December 2020

A single and multiple dose pharmacokinetic and metabolism study of meclofenamate sodium

1 reference

12 December 2020

Preclinical evaluation of the therapeutic effect of adenoviral vectors in human papillomavirus-dependent neoplasias.

1 reference

12 December 2020

Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis

1 reference

12 December 2020